Octreotide shortage — CA supply status & alternatives

Octreotide

ATC H01CB02

🇦🇺 AUST R 311224 · Sun Pharma ANZ Pty Ltd

In supply · Australia

GH octreotide as acetate

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US🇮🇹 IT🇳🇿 NZ🇧🇪 BE🇳🇱 NL

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$14.00details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Octreotide
Brand names	GH octreotide as acetate
ATC level 5	H01CB02
ATC level 4	H01CB
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
Controlled substance	No
Marketing-authorisation holders	Sun Pharma ANZ Pty Ltd, Teva Pharma Australia Pty Ltd, CHEMI SPA MILAN ITALY, Hospira UK Limited +6 more
Registrations on file	30
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$14.00

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

octreotide 50 microgram/mL injection, 5 x 1 mL ampoules

Source: PBSEffective July 2026 · AUD

Other markets

🇺🇸 US

US$2.74

Acquisition

🇮🇹 IT

€15.99

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 3 resolved events

◷

23–27 months

Historical pattern from resolved shortage records — not a prediction of this event.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

22 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Matrix Pharmacorp Private LTDShilpa Pharma Lifesciences LTDSinopep-Allsino Biopharmaceutical CO LTDAlembic Pharmaceuticals LTDPolypeptide Laboratories INCSun Pharmaceutical Industries LTD+16 more

Manufacturing countries: India, China, Spain, Italy, United States, Taiwan, Switzerland · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇨🇦

Canada

HC · 1h ago

High

🇳🇿

New Zealand

Pharmac · 12d ago

High

🇺🇸

United States

ANSM Ruptures · 3mo ago

High

🇮🇹

Italy

AIFA · 1d ago

Medium

🇳🇱

Netherlands

CBG-MEB · 2d ago

Medium

🇧🇪

FAMHP · 12d ago

Medium

🇦🇺

Australia

TGA · 2d ago

Resolved

Recalls official enforcement reports

🌐

Mycapssa

Amryt Pharmaceuticals DAC · Feb 2025

Class Unifieddetails ↗

Verified timeline regulator events

🇳🇱 17 June 2026

medium reported

🇧🇪 15 June 2026

medium reported

🇳🇱 5 June 2026

medium reported

🇳🇱 3 June 2026

medium reported

🇳🇱 27 May 2026

medium reported

🇳🇱 20 May 2026

medium reported

Sources official regulators

🇨🇦

verified 1h ago

verify ↗

🇮🇹

AIFA

verified 1d ago

verify ↗

🇳🇱

CBG-MEB

verified 2d ago

verify ↗

🇦🇺

TGA

verified 2d ago

verify ↗

🇧🇪

FAMHP

verified 12d ago

verify ↗

🇳🇿

Pharmac

verified 12d ago

verify ↗

🇺🇸

ANSM Ruptures

verified 3mo ago

verify ↗

🇺🇸

FDA MedWatch

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders30 registrations · 10 MA holders

Product	Strength	Form	Market	MA holder	Status
Sun	500 microgram	—	🇦🇺 AU	Sun Pharma ANZ Pty Ltd	Active
Depot	20 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
Depot	30 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
Depot	10 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
OCTREOTIDE 50 MICROGRAMS/ML SOLUTION FOR INJECTION IN PREFILLED SYRINGE	50 MICROGRAM	injection	🇬🇧 GB	CHEMI SPA MILAN ITALY	Active
OCTREOTIDE 100 MICROGRAMS/ML SOLUTION FOR INJECTION IN PREFILLED SYRINGE	100 MICROGRAM	injection	🇬🇧 GB	CHEMI SPA MILAN ITALY	Active
OCTREOTIDE 500 MICROGRAMS/ML SOLUTION FOR INJECTION IN PREFILLED SYRINGE	500 MICROGRAM	injection	🇬🇧 GB	CHEMI SPA MILAN ITALY	Active
OCTREOTIDE 50 MICROGRAMS/1 ML SOLUTION FOR INJECTION	50 MICROGRAM	injection	🇬🇧 GB	Hospira UK Limited	Active
OCTREOTIDE 100 MICROGRAMS/1 ML SOLUTION FOR INJECTION	100 MICROGRAM	injection	🇬🇧 GB	Hospira UK Limited	Active
OCTREOTIDE 500 MICROGRAMS/1 ML SOLUTION FOR INJECTION	500 MICROGRAM	injection	🇬🇧 GB	Hospira UK Limited	Active
OCTREOTIDE AMPOULES 50 MCG/ML SOLUTION FOR INJECTION OR CONCENTRATE FOR SOLUTION FOR INFUSION	50 MCG	injection	🇬🇧 GB	NOVARTIS IRELAND LIMITED	Active
OCTREOTIDE AMPOULES 100 MCG/ML SOLUTION FOR INJECTION OR CONCENTRATE FOR SOLUTION FOR INFUSION	100 MCG	injection	🇬🇧 GB	NOVARTIS IRELAND LIMITED	Active
OCTREOTIDE AMPOULES 500 MCG/ML SOLUTION FOR INJECTION OR CONCENTRATE FOR SOLUTION FOR INFUSION	500 MCG	injection	🇬🇧 GB	NOVARTIS IRELAND LIMITED	Active
OCTREOTIDE 50 MICROGRAMS/ML SOLUTION FOR INJECTION	50 MICROGRAM	injection	🇬🇧 GB	SUN PHARMACEUTICAL INDUSTRIES EUROPE BV	Active
OCTREOTIDE 100 MICROGRAMS/ML SOLUTION FOR INJECTION	100 MICROGRAM	injection	🇬🇧 GB	SUN PHARMACEUTICAL INDUSTRIES EUROPE BV	Active

+15 more registrations on file

Mederti Drug Report

Generated 3 July 2026 · Australia market · 8 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.